CompletedPhase 1NCT03340597

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

Studying Aspergillosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
F2G Biotech GmbH
Principal Investigator
Jim Bush, MB ChB PhD MRCS FFPM
Covance CRU Ltd
Intervention
F901318(drug)
Enrollment
45 enrolled
Eligibility
18-55 years · All sexes
Timeline
2017 – 2018

Study locations (1)

Collaborators

Covance

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03340597 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis →

← Back to all trials